Datapoint: Regence Sees 95% Biosimilar Adoption

Regence, the parent company of four Blues affiliates in Idaho, Oregon, Utah and Washington, last week said it has reduced specialty drug spend by $37 million after transitioning to the use of biosimilars. The company said it currently has a 95% adoption rate of biosimilars among its health plan members, and it expects costs to further decrease as more biosimilars become available in 2023. Regence’s four MCOs currently enroll 2,012,243 people in primary medical coverage, with 39.0% enrolled in risk-based commercial plans, and 54.4% in non-risk ASO plans.

Source: AIS’s Directory of Health Plans

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
November 23

Datapoint: Apellis Gets Updated Review Date for Eye Blockbuster Hopeful

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
November 17

Datapoint: Sanford, Fairview Health Announce Merger

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
November 16

Datapoint: California MA Plan to Shutter for 2023

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today